INAB

IN8bio, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer treatment. The company's innovative approach focuses on harnessing the unique properties of gamma-delta T cells, which can recognize and kill cancer cells without requiring HLA matching. IN8bio's lead programs target both hematological malignancies and solid tumors using allogeneic (off-the-shelf) gamma-delta T cell products. The company's technology platform aims to deliver more accessible and affordable cell therapies with reduced risk of graft-versus-host disease and improved manufacturing scalability.